Michael Nurmohamed
Overview
Explore the profile of Michael Nurmohamed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vasileiadis G, Zhang Y, Fatima T, van Vollenhoven R, Lampa J, Gudbjornsson B, et al.
ACR Open Rheumatol
. 2024 Nov;
7(1):e11756.
PMID: 39496558
Objective: The objective of this study was to determine if baseline adiponectin, leptin, and resistin levels are associated with response to antirheumatic treatment in early rheumatoid arthritis (RA). Methods: This...
2.
Liu J, Idborg H, Korotkova M, Lend K, van Vollenhoven R, Lampa J, et al.
Arthritis Res Ther
. 2024 Mar;
26(1):61.
PMID: 38444034
Background: Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient's response to these therapies. Prostanoids, encompassing prostaglandins,...
3.
Lend K, van Vollenhoven R, Lampa J, Hetland M, Haavardsholm E, Nordstrom D, et al.
Lancet Rheumatol
. 2024 Jan;
4(10):e688-e698.
PMID: 38265967
Background: Rheumatoid arthritis is a chronic inflammatory disease with a well-recognised female preponderance. In this post-hoc analysis of the NORD-STAR trial, we aimed to examine sex differences in remission rates...
4.
Lend K, Koopman F, Lampa J, Jansen G, Hetland M, Uhlig T, et al.
Arthritis Rheumatol
. 2023 Oct;
76(3):363-376.
PMID: 37846618
Objective: We investigated methotrexate safety and the influence of dose on efficacy outcomes in combination with three different biologic treatments and with active conventional treatment (ACT) in early rheumatoid arthritis...
5.
Aldridge J, Lundell A, Andersson K, Mark L, Hetland M, Ostergaard M, et al.
Clin Exp Rheumatol
. 2021 Nov;
40(7):1393-1402.
PMID: 34796837
Objectives: In early rheumatoid arthritis (eRA) plasma levels of specific chemokines have been shown to correlate with disease activity. However, it is unclear whether pre-treatment chemokine levels can predict disease...
6.
Agca R, Smulders Y, Nurmohamed M
Heart
. 2021 Mar;
108(1):73-79.
PMID: 33674356
No abstract available.
7.
Hetland M, Haavardsholm E, Rudin A, Nordstrom D, Nurmohamed M, Gudbjornsson B, et al.
BMJ
. 2020 Dec;
371:m4328.
PMID: 33268527
Objective: To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active conventional treatment in patients with early rheumatoid arthritis. Design: Investigator initiated,...
8.
Favorable effects on the hemostatic system in ankylosing spondylitis patients treated with golimumab
Visman I, Heslinga M, van Denderen C, van der Horst-Bruinsma I, Miltenburg A, Meijers J, et al.
Joint Bone Spine
. 2020 Nov;
88(2):105102.
PMID: 33166729
No abstract available.
9.
Vedder D, Walrabenstein W, Heslinga M, de Vries R, Nurmohamed M, van Schaardenburg D, et al.
Nutrients
. 2019 Dec;
11(12).
PMID: 31817107
Gout is one of the most prevalent inflammatory rheumatic disease. It is preceded by hyperuricemia and associated with an increased risk for cardiovascular disease, both related to unhealthy diets. The...
10.
van Vollenhoven R, Nurmohamed M
N Engl J Med
. 2019 Jun;
380(23):2276-2277.
PMID: 31167066
No abstract available.